Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.

Msaouel P, Tannir NM, Walker CL.

Clin Cancer Res. 2018 Feb 12. pii: clincanres.3296.2017. doi: 10.1158/1078-0432.CCR-17-3296. [Epub ahead of print]

PMID:
29440190
2.

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK.

J Clin Oncol. 2018 Jan 29:JCO2017752170. doi: 10.1200/JCO.2017.75.2170. [Epub ahead of print]

PMID:
29377755
3.

Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery.

Jensen G, Tang C, Hess KR, Bishop AJ, Pan HY, Li J, Yang JN, Tannir NM, Amini B, Tatsui C, Rhines L, Brown PD, Ghia AJ.

J Radiosurg SBRT. 2017;5(1):25-34.

4.

BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.

Pan T, Lin SC, Yu KJ, Yu G, Song JH, Lewis VO, Bird JE, Moon B, Lin PP, Tannir NM, Jonasch E, Wood CG, Gallick GE, Yu-Lee LY, Lin SH, Satcher RL.

Neoplasia. 2018 Jan;20(1):32-43. doi: 10.1016/j.neo.2017.11.002. Epub 2017 Nov 27.

5.

Cryoablation of Bone Metastases from Renal Cell Carcinoma for Local Tumor Control.

Gardner CS, Ensor JE, Ahrar K, Huang SY, Sabir SH, Tannir NM, Lewis VO, Tam AL.

J Bone Joint Surg Am. 2017 Nov 15;99(22):1916-1926. doi: 10.2106/JBJS.16.01182.

PMID:
29135665
6.

Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.

Kang HC, Gupta S, Wei W, Lu L, Matrana MR, Tannir NM, Choi H.

AJR Am J Roentgenol. 2017 Dec;209(6):1278-1284. doi: 10.2214/AJR.17.18018. Epub 2017 Oct 24.

7.

Glycemic index, glycemic load and carbohydrate intake in association with risk of renal cell carcinoma.

Zhu J, Tu H, Matin SF, Tannir NM, Wood CG, Wu X.

Carcinogenesis. 2017 Oct 26;38(11):1129-1135. doi: 10.1093/carcin/bgx083.

PMID:
28968893
8.

A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer.

Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, House HL, Lim ZD, Lim KH, Lopez G, Reddy A, Azhar A, Wong A, Patel SM, Kuban DA, Kaseb AO, Cohen L, Bruera E.

J Natl Compr Canc Netw. 2017 Sep;15(9):1111-1120. doi: 10.6004/jnccn.2017.0149.

PMID:
28874596
9.

Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma.

Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY.

Clin Genitourin Cancer. 2017 Aug 10. pii: S1558-7673(17)30238-0. doi: 10.1016/j.clgc.2017.07.028. [Epub ahead of print]

PMID:
28870517
10.

Editorial Comment.

Shah AY, Tannir NM.

Urology. 2017 Nov;109:132. doi: 10.1016/j.urology.2017.06.049. Epub 2017 Sep 1. No abstract available.

PMID:
28867144
11.

Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.

Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA.

Cancer. 2017 Dec 15;123(24):4823-4831. doi: 10.1002/cncr.30937. Epub 2017 Aug 22.

PMID:
28832979
12.

Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma.

Flippot R, Mouawad R, Spano JP, Rouprêt M, Compérat E, Bitker MO, Parra J, Vaessen C, Allanic F, Manach Q, Tannir NM, Khayat D, Su X, Malouf GG.

Sci Rep. 2017 Aug 17;7(1):8540. doi: 10.1038/s41598-017-08363-6.

13.

HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.

Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E.

Cancer Res. 2017 Oct 1;77(19):5313-5326. doi: 10.1158/0008-5472.CAN-17-0986. Epub 2017 Aug 14.

PMID:
28807937
14.

NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas.

Su X, Zhang J, Mouawad R, Compérat E, Rouprêt M, Allanic F, Parra J, Bitker MO, Thompson EJ, Gowrishankar B, Houldsworth J, Weinstein JN, Tost J, Broom BM, Khayat D, Spano JP, Tannir NM, Malouf GG.

Cancer Res. 2017 Sep 15;77(18):4835-4845. doi: 10.1158/0008-5472.CAN-17-0143. Epub 2017 Jul 28.

PMID:
28754676
15.

Recommendations for the Management of Rare Kidney Cancers.

Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A.

Eur Urol. 2017 Dec;72(6):974-983. doi: 10.1016/j.eururo.2017.06.040. Epub 2017 Jul 16. Review.

PMID:
28720391
16.

Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials.

Tannir NM, Figlin RA, Gore ME, Michaelson MD, Motzer RJ, Porta C, Rini BI, Hoang C, Lin X, Escudier B.

Clin Genitourin Cancer. 2017 Jun 20. pii: S1558-7673(17)30171-4. doi: 10.1016/j.clgc.2017.06.005. [Epub ahead of print]

PMID:
28711490
17.

Renal Medullary Carcinoma: Establishing Standards in Practice.

Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK.

J Oncol Pract. 2017 Jul;13(7):414-421. doi: 10.1200/JOP.2017.020909.

PMID:
28697319
18.

Papillary Renal Cell Carcinoma: A Family Portrait.

Flippot R, Compérat E, Tannir NM, Malouf GG.

Eur Urol. 2018 Jan;73(1):79-80. doi: 10.1016/j.eururo.2017.06.004. Epub 2017 Jun 19. No abstract available.

PMID:
28642022
19.

Potential Susceptibility Loci Identified for Renal Cell Carcinoma by Targeting Obesity-Related Genes.

Shu X, Purdue MP, Ye Y, Tu H, Wood CG, Tannir NM, Wang Z, Albanes D, Gapstur SM, Stevens VL, Rothman N, Chanock SJ, Wu X.

Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1436-1442. doi: 10.1158/1055-9965.EPI-17-0141. Epub 2017 Jun 16.

PMID:
28626070
20.

Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.

Malouf GG, Joseph RW, Shah AY, Tannir NM.

Clin Adv Hematol Oncol. 2017 May;15(5):409-418. Review.

PMID:
28591094
21.

Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.

Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Zhang S, Matin S, Karam JA, Wood CG, Wu X.

Cancer. 2017 Sep 15;123(18):3617-3627. doi: 10.1002/cncr.30707. Epub 2017 May 23.

PMID:
28543182
22.

Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.

Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM.

J Urol. 2017 Sep;198(3):530-537. doi: 10.1016/j.juro.2017.04.067. Epub 2017 Apr 11.

PMID:
28411072
23.

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

Tannir NM, Schwab G, Grünwald V.

Curr Oncol Rep. 2017 Feb;19(2):14. doi: 10.1007/s11912-017-0566-9. Review.

24.

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK.

Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.

PMID:
28220024
25.

Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.

Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E.

Clin Genitourin Cancer. 2017 Jun;15(3):363-370. doi: 10.1016/j.clgc.2017.01.010. Epub 2017 Jan 18.

PMID:
28216278
26.

Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.

Msaouel P, Zurita AJ, Huang S, Jonasch E, Tannir NM.

Oncotarget. 2017 Jun 27;8(26):42149-42158. doi: 10.18632/oncotarget.15011.

27.

Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.

Classe M, Malouf GG, Su X, Yao H, Thompson EJ, Doss DJ, Grégoire V, Lenobin J, Fantoni JC, Sudour-Bonnange H, Khayat D, Aubert S, Tannir NM, Leroy X.

Histopathology. 2017 Jun;70(7):1089-1097. doi: 10.1111/his.13167. Epub 2017 Mar 21.

PMID:
28106924
28.

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM.

Ann Oncol. 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676.

PMID:
28049139
29.

MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity.

Shu X, Hildebrandt MA, Gu J, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X.

Br J Cancer. 2017 Jan 3;116(1):77-84. doi: 10.1038/bjc.2016.392. Epub 2016 Dec 1.

30.

Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.

Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM.

BJU Int. 2017 Dec;120(6):782-792. doi: 10.1111/bju.13705. Epub 2016 Dec 9.

PMID:
27860149
31.

Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time?

Msaouel P, Malouf GG, Tannir NM.

Eur Urol. 2017 Mar;71(3):415-416. doi: 10.1016/j.eururo.2016.10.034. Epub 2016 Nov 2. No abstract available.

PMID:
27816301
32.

Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.

Matrana MR, Baiomy A, Campbell M, Alamri S, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Elsayes KM, Tannir NM.

Clin Genitourin Cancer. 2017 Apr;15(2):e205-e208. doi: 10.1016/j.clgc.2016.07.016. Epub 2016 Jul 22.

PMID:
27568124
33.

Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups.

de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen EM, Choueiri TK.

Cancer Immunol Res. 2016 Oct;4(10):820-822. Epub 2016 Aug 18.

34.

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR.

J Clin Oncol. 2016 Oct 10;34(29):3562-3569. doi: 10.1200/JCO.2016.68.1106.

35.

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.

Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P.

J Immunother Cancer. 2016 Jun 21;4:36. doi: 10.1186/s40425-016-0139-8. eCollection 2016.

36.

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators.

Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.

PMID:
27279544
37.

DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.

Malouf GG, Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Raynal NJ, Karam JA, Tamboli P, Allanick F, Mouawad R, Spano JP, Khayat D, Wood CG, Jelinek J, Tannir NM.

Clin Cancer Res. 2016 Dec 15;22(24):6236-6246. Epub 2016 Jun 2.

38.

Stereotactic Body Radiation Therapy for Spinal Metastases in the Postoperative Setting: A Secondary Analysis of Mature Phase 1-2 Trials.

Tao R, Bishop AJ, Brownlee Z, Allen PK, Settle SH, Chang EL, Wang X, Amini B, Tannir NM, Tatsui C, Rhines LD, Brown PD, Ghia AJ.

Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1405-1413. doi: 10.1016/j.ijrobp.2016.03.022. Epub 2016 Mar 25. Review.

PMID:
27209509
39.

Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support.

Milbury K, Lopez G, Spelman A, Wood C, Matin SF, Tannir NM, Jonasch E, Pisters L, Wei Q, Cohen L.

Psychooncology. 2017 Sep;26(9):1361-1368. doi: 10.1002/pon.4148. Epub 2016 May 3.

40.

The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis.

Thomas AZ, Adibi M, Slack RS, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA.

J Urol. 2016 Sep;196(3):678-84. doi: 10.1016/j.juro.2016.03.144. Epub 2016 Mar 29.

41.

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.

Chittoria N, Haddad H, Elson P, Tannir NM, Wood LS, Dreicer R, Garcia JA, Rini BI, Jonasch E.

BMC Cancer. 2016 Mar 29;16:254. doi: 10.1186/s12885-016-2282-5.

42.

Personalised cancer care: promises and challenges of targeted therapy.

Tu SM, Bilen MA, Tannir NM.

J R Soc Med. 2016 Mar;109(3):98-105. doi: 10.1177/0141076816631154. Epub 2016 Mar 1. No abstract available.

PMID:
26933155
43.

Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.

Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Khayat D, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA.

Eur Urol. 2016 Aug;70(2):348-57. doi: 10.1016/j.eururo.2016.01.051. Epub 2016 Feb 16.

PMID:
26895810
44.

Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of Phase I/II trials.

Ghia AJ, Chang EL, Bishop AJ, Pan HY, Boehling NS, Amini B, Allen PK, Li J, Rhines LD, Tannir NM, Tatsui CE, Brown PD, Yang JN.

J Neurosurg Spine. 2016 May;24(5):829-36. doi: 10.3171/2015.8.SPINE15844. Epub 2016 Jan 22.

PMID:
26799117
45.

Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy.

Borregales LD, Kim DY, Staller AL, Qiao W, Thomas AZ, Adibi M, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA.

Urol Oncol. 2016 May;34(5):237.e19-26. doi: 10.1016/j.urolonc.2015.11.020. Epub 2015 Dec 18.

46.

Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study.

Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Matin SF, Karam JA, Huang M, Chang DW, Wood CG, Wu X.

Clin Cancer Res. 2016 Apr 15;22(8):2074-82. doi: 10.1158/1078-0432.CCR-15-0977. Epub 2015 Dec 11.

47.

Can the spinal instability neoplastic score prior to spinal radiosurgery predict compression fractures following stereotactic spinal radiosurgery for metastatic spinal tumor?: a post hoc analysis of prospective phase II single-institution trials.

Lee SH, Tatsui CE, Ghia AJ, Amini B, Li J, Zavarella SM, Tannir NM, Brown PD, Rhines LD.

J Neurooncol. 2016 Feb;126(3):509-17. doi: 10.1007/s11060-015-1990-z. Epub 2015 Dec 7.

PMID:
26643804
48.

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.

Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK.

Eur Urol. 2016 May;69(5):866-74. doi: 10.1016/j.eururo.2015.10.049. Epub 2015 Nov 26.

49.

Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.

Matrana MR, Bathala T, Campbell MT, Duran C, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM.

BJU Int. 2016 Aug;118(2):264-71. doi: 10.1111/bju.13374. Epub 2015 Dec 13.

50.

Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma.

Melkonian SC, Daniel CR, Ye Y, Tannir NM, Karam JA, Matin SF, Wood CG, Wu X.

Cancer. 2016 Jan 1;122(1):108-15. doi: 10.1002/cncr.29543. Epub 2015 Nov 9.

Supplemental Content

Loading ...
Support Center